APA (7th ed.) Citation

C, X., T, Y., S, W., C, W., T, C., E, K., & H, L. (2026). Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 40(3), 459. https://doi.org/10.1007/s40259-026-00769-x

Chicago Style (17th ed.) Citation

C, Xu, Yan T, Wen S, Wu C, Chang T, Kong E, and Liu H. "Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 40, no. 3 (2026): 459. https://doi.org/10.1007/s40259-026-00769-x.

MLA (9th ed.) Citation

C, Xu, et al. "Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 40, no. 3, 2026, p. 459, https://doi.org/10.1007/s40259-026-00769-x.